Weiss RB, Grillo-López AJ, Marsoni S, Posada JG, Hess F, Ross BJ

Amsacrine-associated cardiotoxicity: an analysis of 82 cases.

J Clin Oncol 1986; 918-28. doi: 10.1200/JCO.1986.4.6.918

Erba E, Ubezio P, Pepe S, Vaghi M, Marsoni S, Torri W, Mangioni C, Landoni F, D'Incalci M

Flow cytometric analysis of DNA content in human ovarian cancers.

Br J Cancer 1989; 45-50. doi: 10.1038/bjc.1989.217

Grilli R, Alexanian A, Apolone G, Fossati R, Marsoni S, Nicolucci A, Torri V, Zola P, Compagnucci M, Di Mambro E

The impact of cancer treatment guidelines on actual practice in Italian general hospitals: the case of ovarian cancer.

Ann Oncol 1990; 112-8. doi: 10.1093/oxfordjournals.annonc.a057687

Estey E, Hoth D, Simon R, Marsoni S, Leyland-Jones B, Wittes R

Therapeutic response in phase I trials of antineoplastic agents.

Cancer Treat Rep 1986; 1105-15.

Marsoni S, Hoth D, Simon R, Leyland-Jones B, De Rosa M, Wittes RE

Clinical drug development: an analysis of phase II trials, 1970-1985.

Cancer Treat Rep 1987; 71-80.

Liberati A, Mangioni C, Bratina L, Carinelli G, Marsoni S, Parazzini F, Regallo M, Talamini R, Tognoni G

Process and outcome of care for patients with ovarian cancer.

Br Med J (Clin Res Ed) 1985; 1007-12. doi: 10.1136/bmj.291.6501.1007

Wittes RE, Marsoni S, Simon R, Leyland-Jones B

The phase II trial.

Cancer Treat Rep 1985; 1235-9.

Eli S, Rauso G, Ghezzi P, Szczerkowski JLA, Bruzzi M, Rizzelli F, Iommazzo F, Loffreda A, Castagna F, Donà F, Gaddoni C, Dondi A, Marenda M, Rodighiero S, Tournier P, Lavagnino Z, Parazzoli D, Gauthier NC, Tamburri S, Pasini D, Habib SJ, Mapelli M

Localized Wnt-signaling promotes asymmetric NuMA-dependent oriented divisions and unequal apportioning of mitochondria.

Nat Commun 2025; 10690. doi: 10.1038/s41467-025-65775-z

Ghersi D, Parmar MK, Stewart LA, Marsoni S, Williams CJ

Early ovarian cancer and the icon trials.

Eur J Cancer 1992; 1297. doi: 10.1016/0959-8049(92)90497-p

%PLACEHOLDER%